Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Trial details
- Registry ID
- NCT00704288
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288 | Exelixis | Phase 2 | Completed | 2012-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |